Welcome to our dedicated page for Genmab news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab stock.
Genmab A/S (GMAB) generates frequent news flow as an international biotechnology company focused on antibody medicines for cancer and other serious diseases. Company announcements highlight advances in its antibody platforms, late‑stage clinical programs, regulatory milestones and corporate transactions, offering investors and observers a detailed view of how its science translates into clinical and commercial progress.
Recent news has emphasized the expanding clinical profile of epcoritamab (EPKINLY), an IgG1‑bispecific antibody created using Genmab’s DuoBody technology. Genmab regularly reports data from Phase 1b/2 and Phase 3 trials in diffuse large B‑cell lymphoma, follicular lymphoma and Richter transformation, including monotherapy and combination regimens with standard treatments such as R‑CHOP, R‑mini‑CHOP, rituximab and lenalidomide, and bendamustine plus rituximab. These updates often include response rates, survival outcomes and safety findings from major oncology congresses.
News coverage also includes developments in Genmab’s wholly owned pipeline, such as updated data for rinatabart sesutecan (Rina‑S) in advanced endometrial cancer and the expansion of its clinical program into Phase 3 trials. Corporate strategy items, including the planned acquisition and subsequent tender offer for Merus N.V. to add petosemtamab to the portfolio, feature prominently in company announcements and SEC‑related communications.
In addition, Genmab reports on initiatives that shape how it conducts research and development, such as its partnership with Anthropic to deploy Claude‑powered agentic AI solutions to support clinical development operations. Visitors to this GMAB news page can review these company announcements, trial readouts, regulatory updates and transaction disclosures to follow how Genmab’s antibody platforms, collaborations and late‑stage assets evolve over time.
Summary not available.
Summary not available.
Summary not available.
Genmab A/S (Nasdaq: GMAB) announced the submission of a Japan New Drug Application (JNDA) for epcoritamab, an investigational bispecific antibody targeting relapsed/refractory large B-cell lymphoma (LBCL). This submission is backed by results from Japanese and global phase 2 clinical trials. Epcoritamab's ongoing development involves collaboration with AbbVie, with shared responsibilities for commercialization in the U.S. and Japan. The treatment shows promise as a therapeutic option for patients requiring alternative therapies.
Genmab A/S (Nasdaq: GMAB) has announced promising results from multiple clinical trials involving epcoritamab, an investigational bispecific antibody targeting B-cell malignancies. Notable findings include an 85% overall response rate in a phase 1b/2 trial for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high response rates in follicular lymphoma. Epcoritamab is co-developed with AbbVie and is undergoing regulatory review, with an FDA action date of May 21, 2023. The breadth of data presented at the American Society of Hematology annual meeting underscores Genmab's commitment to addressing critical treatment needs.
Genmab (NASDAQ: GMAB) announced the acceptance of 19 abstracts for the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, showcasing investigational therapies including epcoritamab. The data will feature four oral presentations on epcoritamab's efficacy in treating various B-cell malignancies. The company will present early data on GEN3014 and GEN3017. A 2022 R&D Update and ASH Data Review meeting is scheduled for December 12.
Genmab has submitted a Biologics License Application (BLA) to the U.S. FDA for epcoritamab, a bispecific antibody targeting relapsed/refractory large B-cell lymphoma. AbbVie has also validated a Marketing Authorization Application (MAA) for epcoritamab with the European Medicines Agency (EMA). These submissions stem from the EPCORE NHL-1 phase 2 trial, showing the drug's safety and efficacy in treating CD20+ mature B-cell non-Hodgkin lymphoma, a significant medical need exists for these patients. The joint development with AbbVie aims to bring new therapeutic options to market.
Zai Lab has secured exclusive rights to develop and commercialize TIVDAK, an FDA-approved antibody-drug conjugate, in Mainland China, Hong Kong, Macau, and Taiwan. The collaboration with Seagen involves a $30 million upfront payment, milestone payments, and shared royalties. TIVDAK addresses a significant unmet need in treating recurrent or metastatic cervical cancer, with 110,000 new cases annually in China. Ongoing clinical trials underpin the therapeutic potential of TIVDAK in various cancer treatments.
Genmab (NASDAQ: GMAB) and BioNTech (NASDAQ: BNTX) have expanded their collaboration to develop novel monospecific antibody candidates aimed at treating malignant solid tumors. The partnership will leverage Genmab's proprietary HexaBody technology, with the first candidate, GEN1053/BNT313, expected to enter clinical trials by the end of 2022. Both companies will share development costs and potential profits equally. This collaboration enhances their oncology pipeline, targeting high unmet medical needs in cancer immunotherapy.
Genmab A/S (Nasdaq: GMAB) announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) to the European Medicines Agency for epcoritamab to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in H2 2022. This follows Genmab's intention to submit a biologics license application (BLA) to the FDA for the same drug. The MAA is supported by preliminary efficacy results from the EPCORE™ NHL-1 trial, emphasizing the significant medical need for new treatment options for patients with DLBCL.